Date | Price Target | Rating | Analyst |
---|---|---|---|
6/28/2021 | $10.00 | Buy | Roth Capital |
4 - Panbela Therapeutics, Inc. (0001029125) (Issuer)
3 - Panbela Therapeutics, Inc. (0001029125) (Issuer)
4 - Panbela Therapeutics, Inc. (0001029125) (Issuer)
S-1/A - Panbela Therapeutics, Inc. (0001029125) (Filer)
424B3 - Panbela Therapeutics, Inc. (0001029125) (Filer)
424B3 - Panbela Therapeutics, Inc. (0001029125) (Filer)
MINNEAPOLIS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended June 30, 2024. As previously announced, management is hosting an earnings call today at 4:30 p.m. ET. Q2 2024 and Recent Highlights: Clinical Phase 3 ASPIRE clinical trial received favorable third independent safety review: DSMB recommended continuation without modification.Completed Oral Presentation at Digestive Disease Week (DDW): Evaluation of the Safety and Efficacy of Eflornithine (Difluoro
MINNEAPOLIS, July 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on Aug 13, 2024, at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2024. Conference Call Information Toll Free: 888-506-0062International: 973-528-0011Participant Access Code: 405072Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/50956 Conference Call Replay Information Toll Free: 877-481-4010International: 919-882-2331Replay Passcode: 50956Webcast Replay: https://www.webc
DSMB Recommends Continuation without Modification for Third TimeSafety Review Included 395 PatientsInterim Survival Analysis Still Expected Early 2025 given Lower-Than-Expected Event Rate Low Event Rate Suggests Potential for Prolonged SurvivalRapid Enrollment Positions Company for Enrollment Completion by Q1 2025; Earlier Than Expected MINNEAPOLIS, June 24, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that the independent Data Safety Monitoring Board (DSMB) has completed its third pre-specified safety
MINNEAPOLIS, July 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on Aug 13, 2024, at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2024. Conference Call Information Toll Free: 888-506-0062International: 973-528-0011Participant Access Code: 405072Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/50956 Conference Call Replay Information Toll Free: 877-481-4010International: 919-882-2331Replay Passcode: 50956Webcast Replay: https://www.webc
MINNEAPOLIS, May 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on May 15, 2024, at 4:30 PM Eastern Time to discuss results for its first quarter ended March 31, 2024. Conference Call Information Toll Free: 877-545-0523International: 973-528-0016Participant Access Code: 234396Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/50531 Conference Call Replay Information Toll Free: 877-481-4010International: 919-882-2331Replay Passcode: 50531Webcast Replay: https://www.webcas
MINNEAPOLIS, March 12, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on March 26, 2024, at 4:30 PM Eastern Time to discuss results for its fourth quarter and year ended December 31, 2023. Conference Call Information Toll Free: 888-506-0062International: 973-528-0011Participant Access Code: 195310Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/49978 Conference Call Replay Information Toll Free: 877-481-4010International: 919-882-2331Replay Passcode: 49978Webcast Replay:
HC Wainwright & Co. analyst Joseph Pantginis reiterates Panbela Therapeutics (OTC:PBLA) with a Neutral.
HC Wainwright & Co. analyst Joseph Pantginis downgrades Panbela Therapeutics (OTC:PBLA) from Buy to Neutral.
Panbela Therapeutics (NASDAQ:PBLA) reported quarterly losses of $(2.28) per share which missed the analyst consensus estimate of $(1.48) by 54.05 percent.
Roth Capital initiated coverage of Panbela Therapeutics with a rating of Buy and set a new price target of $10.00
Maxim Group initiated coverage of Panbela Therapeutics with a rating of Buy and set a new price target of $8.00
Maxim Group initiated coverage of Panbela Therapeutics with a rating of Buy and set a new price target of $8.00
SC 13G/A - Panbela Therapeutics, Inc. (0001029125) (Subject)
SC 13G/A - Panbela Therapeutics, Inc. (0001029125) (Subject)
SC 13G - Panbela Therapeutics, Inc. (0001029125) (Subject)